Add as a preferred source on GoogleHalozyme Therapeutics Raises 2026 Revenue Outlook After Q3 Beat
Third-quarter revenue rose 39% year over year to $493 million, while non-GAAP earnings per share reached $2.39, 3 cents above estimates.
A stronger third quarter led Halozyme Therapeutics to lift its full-year 2026 revenue outlook, with sales for the latest period reaching $493 million and non-GAAP earnings topping estimates.
Revenue increased 39% from the year-earlier quarter. The company's non-GAAP calculation put earnings at $2.39 per share, 3 cents above estimates; revenue was $1.44 million higher than estimated.
Halozyme now projects 2026 total revenue of $1.86 billion to $1.925 billion, a year-over-year increase of 33% to 38%. Its outlook for royalty revenue is $1.235 billion to $1.255 billion, representing growth of 42% to 45% from a year earlier.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.